AC
BCRX icon

AXQ Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

AXQ Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$545K Buy
54,534
+15,582
+40% +$141K 0.06% 457
2026
Q1 		$371K Buy
+38,952
New +$302K 0.05% 518
2025
Q4 		– Sell
-58,423
Closed -$443K – 735
2025
Q3 		$443K Buy
58,423
+45,106
+339% +$376K 0.17% 216
2025
Q2 		$119K Buy
+13,317
New +$124K 0.04% 505
2023
Q4 		– Sell
-23,134
Closed -$164K – 645
2023
Q3 		$164K Buy
23,134
+5,600
+32% +$40.2K 0.06% 403
2023
Q2 		$123K Sell
17,534
-1,300
-7% -$10.4K 0.15% 229
2023
Q1 		$157K Buy
+18,834
New +$181K 0.06% 425

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AXQ Capital's BCRX Position: Q2 2026 in Review

AXQ Capital increased its BioCryst Pharmaceuticals (BCRX) stake by 40% in Q2 2026, buying an estimated $141K and bringing the position to 54,534 shares worth $545K. The position accounts for 0.06% of the portfolio, ranked #457.

AXQ Capital first reported a position in BCRX in Q1 2023 and has held it in 7 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • AXQ Capital held 54,534 shares of BioCryst Pharmaceuticals worth $545K as of Q2 2026.
  • AXQ Capital bought 15,582 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $141K.
  • BioCryst Pharmaceuticals made up 0.06% of AXQ Capital's portfolio in Q2 2026, its #457 holding.
  • AXQ Capital first reported a position in BioCryst Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.